公开(公告)号：US20190383818A1

公开(公告)日：2019-12-19

申请号：US16464744

申请日：2017-11-29

Applicant: KONICA MINOLTA, INC. ,  HIROSAKI UNIVERSITY

Inventor： Tomonori KANEKO ,  Takatoshi KAYA ,  Chikara OHYAMA ,  Tohru YONEYAMA ,  Yuki TOBISAWA

IPC: G01N33/574 ,  G01N21/64

Abstract: The present invention provides methods that are for acquiring various types of supplementary information used for diagnosis or treatment of prostate cancer, and that can be implemented in a less-invasive manner at a low cost. Provided are, by measuring the content of prostate specific antigen (PSA) having a β-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain in a specimen, and comparing the measured value with a threshold value, (1) a method for estimating whether a Gleason score (primary pattern and secondary pattern) is not less than or less than a prescribed value, (2) a method for estimating whether the pathological stage (pT) is not less than or less than a prescribed value, and (3) a method for acquiring information for assessment indicating diagnosis or treatment should be actively conducted because a GS at gross total removal is expected to be higher than a GS at biopsy.

公开(公告)号：US20210318317A1

公开(公告)日：2021-10-14

申请号：US17272848

申请日：2019-09-25

Applicant: Konica Minolta, Inc.

Inventor： Tomonori KANEKO ,  Takatoshi KAYA ,  Chikara OHYAMA ,  Tohru YONEYAMA ,  Yuki TOBISAWA ,  Osamu OGAWA ,  Takahiro INOUE

IPC: G01N33/574 ,  G16B40/00 ,  G01N21/65

Abstract: The present invention provides a method for acquiring auxiliary information useful to assist a diagnosis or treatment of prostate cancer. The method for acquiring auxiliary information of the present invention is a method for acquiring auxiliary information to assist a diagnosis or treatment of prostate cancer, and includes a step (C) of dividing a concentration value of a prostate specific antigen having a β-N-acetylgalactosamine residue at a non-reducing terminal of a sugar chain, contained in a sample derived from a living body, by a volume value of prostate of the living body to calculate the concentration value of the GalNAc-PSA per prostate volume.